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A LARGE OUTBREAK OF CLOSTRIDIUM
DIFFICILE–ASSOCIATED DISEASE WITH AN UNEXPECTED
PROPORTION OF DEATHS AND COLECTOMIES AT A
TEACHING HOSPITAL FOLLOWING INCREASED
FLUOROQUINOLONE USE
Carlene A. Muto, MD, MS; Marian Pokrywka, MPH, BS, CIC; Kathleen Shutt, MS; Aaron B. Mendelsohn, PhD; 
Kathy Nouri, MPH, RN, BSN, CIC; Kathy Posey, MPH, BS, CIC; Terri Roberts, BS, CIC; Karen Croyle, BS, CIC; 
Sharon Krystofiak, MPH, MS, CIC; Sujata Patel-Brown, BS; A. William Pasculle, ScD; David L. Paterson, MD; 
Melissa Saul, MS; Lee H. Harrison, MD
Clostridium dif ficile is the most common cause of
acute care hospital–acquired diarrhea, accounting for
approximately 15% to 30% of all cases of antibiotic-associ-
ated diarrhea1-3 and more than 300,000 cases per year.4,5
The incidence has been reported to vary from 1 to 30
cases per 1,000 patient discharges.6-8 Severe disease has
been reported to occur in approximately 3% of infected
patients and is associated with toxic megacolon, perfora-
tion, colectomy, and death.9,10 The estimated attributable
healthcare cost of C. dif ficile infection is $3,669 per case.11
The antibiotics considered to be associated with 
the highest risk of C. dif ficile disease include clin-
damycin,6,8,12-15 cephalosporins,16-20 and ampicillin–amoxi-
cillin.21,22 Fluoroquinolones were not generally considered
to be a major risk factor for antibiotic-associated diar-
rhea.23 However, the experience with many of the newer
agents in this class is limited, and reports of an associa-
tion between C. dif ficile colitis and fluoroquinolone use
have recently emerged.7,20,24-32
From 1999 to 2000–2001, the incidence of nosoco-
mial C. dif ficile disease at our hospital increased from 2.7
to 6.8 cases per 1,000 discharges (P < .001) or 0.46 to 1.12
cases per 1,000 patient-days. In 1999, 4 (5.6%) of 72
patients with nosocomial C. dif ficile had severe disease
representing 0.15 severe case per 1,000 discharges.
During 2000 and 2001, 37 (8.8%) of 419 cases resulted in
severe outcomes corresponding to an increased rate of
0.60 severe case per 1,000 discharges (P = .004). There
were 37 severe nosocomial cases during this 2-year peri-
od, 26 patients had C. dif ficile–associated colectomy, and
18 patients had C. dif ficile–associated death. 
These findings prompted a review of the 2,334
patients hospitalized with C. dif ficile colitis from January
1989 to December 2000.33 The increased incidence of C.
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BACKGROUND AND OBJECTIVE: Fluoroquinolones
have not been frequently implicated as a cause of Clostridium difficile
outbreaks. Nosocomial C. difficile infections increased from 2.7 to 6.8
cases per 1,000 discharges (P < .001). During the first 2 years of the
outbreak, there were 253 nosocomial C. difficile infections; of these,
26 resulted in colectomy and 18 resulted in death. We conducted an
investigation of a large C. difficile outbreak in our hospital to identify
risk factors and characterize the outbreak. 
METHODS: A retrospective case–control study of case-
patients with C. dif ficile infection from January 2000 through
April 2001 and control-patients matched by date of hospital
admission, type of medical service, and length of stay; an analy-
sis of inpatient antibiotic use; and antibiotic susceptibility testing
and molecular subtyping of isolates were performed.
RESULTS: On logistic regression analysis, clindamycin
(odds ratio [OR], 4.8; 95% confidence interval [CI95], 1.9–12.0),
ceftriaxone (OR, 5.4; CI95, 1.8–15.8), and levofloxacin (OR, 2.0;
CI95, 1.2–3.3) were independently associated with infection. The
etiologic fractions for these three agents were 10.0%, 6.7%, and
30.8%, respectively. Fluoroquinolone use increased before the
onset of the outbreak (P < .001); 59% of case-patients and 41% of
control-patients had received this antibiotic class. The outbreak
was polyclonal, although 52% of isolates belonged to two highly
related molecular subtypes. 
CONCLUSIONS: Exposure to levofloxacin was an inde-
pendent risk factor for C. dif ficile–associated diarrhea and
appeared to contribute substantially to the outbreak. Restricted
use of levofloxacin and the other implicated antibiotics may be
required to control the outbreak (Infect Control Hosp Epidemiol
2005;26:273-280).
ABSTRACT
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dif ficile colitis was accompanied by an increased propor-
tion of cases associated with severe adverse outcomes as
compared with the historical data, and a 1:3 matched
case–control risk factor analysis was done to evaluate 16
patients who required colectomies in 2000.34 Case-
patients were matched to control-patients by age and
occurrence of C. dif ficile colitis within the same period.
Chronic lung disease and elevated white blood cell count
were found to be significant in the regression model.
Transplantation and immunosuppression were not signifi-
cant risk factors. Exposure to levofloxacin was noted to be
high (64%) in all patients studied. This study prompted an
investigation to identify risk factors for C. dif ficile acquisi-
tion and to characterize this outbreak. 
METHODS 
The University of Pittsburgh Medical Center–
Presbyterian Hospital is a 600-bed, tertiary-care teaching
facility affiliated with the University of Pittsburgh Schools
of the Health Sciences. The University of Pittsburgh
Medical Center–Presbyterian Hospital consists of two
hospitals connected by a pedestrian bridge. In general,
hospital A houses the medical services and hospital B
houses the surgical services. 
The outbreak began in January 2000 and continued
throughout 2002. Before the epidemic period, there was
no obvious change in patient population, infection control
policies, or laboratory tests used to identify C. dif ficile.
The only formulary changes were switches from cef-
tazidime to cefepime in April 1998 and from ciprofloxacin
to levofloxacin in March 1999. 
Alcohol sanitizer was introduced into our hospital in
July 2000, 7 months after the outbreak began. This is an
important point because it has been postulated that disin-
fecting hands may be less effective in decreasing transmis-
sion because alcohol has poor activity against C. difficile
spores. 
Various infection control interventions were imple-
mented in response to the outbreak. These included an
education program, efforts to quickly identify and isolate
patients with C. dif ficile, verbal and electronic communi-
cation of suspected disease along with isolation require-
ments (private room or cohorting and gown, gloves, and
hand hygiene for all patient or environmental contact),
development of an electronic isolation code to readily
visualize C. dif ficile status on various electronic patient
record systems and block placement of non-coded
patients in the same room, and the implementation of
enhanced hypochlorite disinfection. Additionally, the
duration of isolation was extended beyond the recom-
mendations of the Centers for Disease Control and
Prevention (duration of illness)35 to the entire length of
stay. Compliance with the infection control strategies was
observed (greater than 93% in more than 300 observa-
tions for contact isolation signage and supply availability,
60% [76 of 127] for donning of appropriate isolation garb,
and 62% for hand hygiene). This did not differ appreciably
from the pre-outbreak period. 
In general, nosocomial C. dif ficile disease was
defined as onset more than 48 hours after admission or
within 3 months of last discharge, if no evidence of prior
positive results or other healthcare in the interim prior to
re-admission. Severe C. difficile disease was defined by the
presence of C. dif ficile toxin–mediated colitis (toxin,
pseudomembranes, or both visualized endoscopically) and
C. difficile–associated colectomy, death, or both. All poten-
tial cases were reviewed by at least two of four trained
physicians to determine whether colectomy or death was
C. difficile associated.
This study consisted of the following three compo-
nents: (1) a case–control study of risk factors for nosocomi-
al C. difficile infection, (2) an analysis of trends of in-patient
antibiotic use for the period before and during the outbreak,
and (3) a microbiologic component that included antimicro-
bial susceptibility testing and molecular subtyping.
Case–Control Study Methods
A matched case–control study was performed for
cases that occurred during the period of January 1, 2000,
to April 30, 2001. A case-patient was defined as a patient
who had C. dif ficile toxin identified in his or her stool at
least 72 hours after admission to the hospital and signs
and symptoms of C. dif ficile disease. For each case-
patient, one control-patient who did not have a positive
result on C. dif ficile toxin assay was matched on date of
admission (± 2 days), type of medical service (medicine vs
surgery), and length of stay in the hospital. The length of
stay of the control-patient had to be at least as long as the
interval between the admission date and the C. dif ficile
toxin positivity date of the case-patient. The date of the
case-patient’s first positive C. dif ficile toxin result was
used to define the reference date for the case-patient and
control-patient.
Most of the data for this study, including medication
histories, demographic information, and laboratory data,
were obtained from our electronic medical archival
retrieval system, composed of hospital databases estab-
lished for patient care and billing purposes.36 Information
on chronic medical conditions and exposures that
occurred outside of our institution was obtained by retro-
spective chart review. 
Antibiotic Trends Analysis Methods
A trend analysis was performed on implicated antibi-
otics to determine whether there was a change in use asso-
ciated with the outbreak. Monthly antibiotic data (in units)
were abstracted from the medical archival retrieval system.
A unit was defined by the specific dose given. All units were
calculated and multiplied by the milligram dose of that unit
and converted to grams. Defined daily doses (DDDs) for
antibiotics were calculated using the standards of the
World Health Organization.37 Monthly DDD rates were cal-
culated per 1,000 patient-days. Monthly DDD rates were
averaged for a 12-month period before the fluoroquinolone
formulary change (period 1, March 1998 to February 1999)
and compared with the rate for the subsequent 12-month
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period (period 2, March 1999 to February 2000). Rates
were again calculated for the next 12-month period (period
3, March 2000 to February 2001) and compared with those
of period 2.
Microbiology Methods
The presence of C. dif ficile toxin in the stool of case-
patients was determined using a standard cell culture
cytotoxicity assay with MRHF/HFF cells (Diagnostic
Hybrids, Inc., Athens, OH) and antitoxin from TechLab
(Blacksburg, VA). Toxin testing was done throughout the
outbreak period. Culturing for C. dif ficile began in March
2001 and was accomplished using previously published
methods.38
Antimicrobial susceptibility testing was performed
on isolates collected between March and August 2001 by
the Etest method (AB Biodisk, Piscataway, NJ) using C.
dif ficile strain American Type Culture Collection 9689 as
a control. Interpretations were according to National
Committee for Clinical Laboratory Standards guidelines39
for the antibiotics for which guidelines were available. For
vancomycin and fluoroquinolones, agents for which
National Committee for Clinical Laboratory Standards cri-
teria were not available, the following values were used:
resistant, minimum inhibitory concentration (MIC) of 8
µg/mL or greater; intermediate, MIC of 4 µg/mL; and
susceptible, MIC of 2 µg/mL or less. We also determined
the proportion of isolates that had a MIC of greater than
32 µg/mL to the fluoroquinolones and a MIC of greater
than 256 µg/mL to clindamycin. 
Restriction enzyme analysis (REA), a common mole-
cular subtyping technique used for C. difficile DNA finger-
printing, was performed on C. difficile isolates collected
between March and December 2001 using a modification of
a previously published method.40 REA types were assigned
based on visual inspection. For isolates to be considered to
have the same REA type, the banding patterns had to be
identical to the prototype isolate for that REA type. In addi-
tion, the identical banding pattern had to be confirmed by
running the isolates in question on the same gel as the 
prototype. 
Statistical Methods 
For the case–control study, matched univariate
analysis using matched odds ratios (ORs) and conditional
logistic regression was performed on all variables.41
Exposures were determined for the 28-day period before C.
difficile positivity for each case-patient and the matched
control-patient. A multivariable model was fit using a step-
wise model-building approach to identify variables inde-
pendently associated with being a case. All variables from
the univariate analyses were eligible for entry into the
model. The stay criterion for the model was a P value of less
than .05. Etiologic fraction (the proportion of disease pre-
sumably caused by the exposure in question) for antibiotics
associated with C. difficile–associated disease was estimat-
ed using the proportion of control-patients exposed to each
antibiotic and the matched OR as an approximation for the
relative risk, as previously described.42 For the antibiotic
trends analysis, the Cox–Stuart test for trend was per-
formed on antibiotic use data from March 1998 through
February 2001.
For analysis of REA typing results, we determined
which hospital units case-patients had been on in the 14
days before the case reference date. Analyses were con-
ducted using the SAS system (version 8.2; SAS Institute,
Inc., Cary, NC). 
Outbreak-Associated Costs
The number and rates of C. dif ficile infections were
calculated at baseline (1999) and during the outbreak
(2000 and 2001). The excess numbers of annual and total
infections during the outbreak were determined, and the
estimated attributable healthcare cost of these additional
infections was calculated by multiplying the number of
excess infections by the estimate of $3,669 per episode.11
RESULTS 
Case–Control Study
Of a total of 447 C. dif ficile toxin–positive patients
who were identified during the study period, 227 (50.8%)
were positive 72 hours or more after hospital admission.
Matched control-patients were identified for 203 (89.4%)
of these case-patients. The remaining 24 case-patients
(10.6%) were excluded because no patients who were
admitted within 2 days of them had stays at least as long
as the time to the case reference date. 
The demographics and clinical characteristics of
the enrolled case-patients and control-patients are provid-
ed in Table 1. On univariate analysis, case-patients were
more likely than control-patients to have had a transplant
(OR, 4.3; 95% confidence interval [CI95], 2.0 to 9.2), dia-
betes mellitus (OR, 1.7; CI95, 1.1 to 2.7), chronic lung dis-
ease (OR, 1.6; CI95, 1.1 to 2.5), or diverticulosis (OR, 3.0;
CI95, 1.2 to 7.6) or be immunosuppressed (OR, 1.9; CI95,
1.2 to 3.1). Multiple medications were associated with
being a case-patient on the univariate analysis (Table 2). 
On the multivariable conditional logistic regression
analysis, age (OR, 1.02 for each year of age; CI95, 1.006 to
1.037), diabetes mellitus (OR, 2.1; CI95, 1.2 to 3.6), organ
transplantation (OR, 5.8; CI95, 2.3 to 14.6), H2 blocker use
(OR, 2.0; CI95, 1.1 to 3.5), and use of proton pump
inhibitors (OR, 2.4; CI95, 1.3 to 4.4) were associated with
being a case-patient. Clindamycin (OR, 4.8; CI95, 1.9 to
12.0), ceftriaxone (OR, 5.4; CI95, 1.8 to 15.8), and lev-
ofloxacin (OR, 2.0; CI95, 1.2 to 3.3) were the antibiotics
associated with C. dif ficile infection. The etiologic frac-
tions for these three agents were 10.0%, 6.7%, and 30.8%,
respectively. Therapy with single antibiotics was relative-
ly uncommon among both case-patients and control-
patients, which did not allow for an assessment of the risk
of monotherapy with these agents. 
Antibiotic Trends
In the analysis of trends of antibiotic use, fluoro-
quinolone use increased significantly from an average of
This content downloaded from 23.235.32.0 on Wed, 21 Oct 2015 20:54:51 PM
All use subject to JSTOR Terms and Conditions
276 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY March 2005
217 DDDs per 1,000 patient-days in period 1 to 275 DDDs
per 1,000 patient-days for period 2 (P < .001). This
increase in fluoroquinolone use preceded the beginning
of the outbreak by 9 months. Cephalosporin use did not
change significantly, with 51 DDDs per 1,000 patient-days
in period 1 versus 66 DDDs per 1,000 patient-days in peri-
od 2 (P = .19), and clindamycin use averaged 28 DDDs per
1,000 patient-days for period 1 and 30 DDDs per 1,000
patient-days for the second 12-month period (P = .01). For
period 3, quinolone use was 310 DDDs per 1,000
patient-days (P = .003 for increase from period 2 to 3),
cephalosporin use was 66 DDDs per 1,000 patient-days 
(P = .6), and clindamycin use was 32 DDDs per 1,000
patient-days (P = .19). 
Antimicrobial Susceptibility
Antimicrobial susceptibility testing was performed
on 91 isolates: 46 nosocomial isolates and 45 isolates
acquired elsewhere. None of the isolates had resistance to
metronidazole or vancomycin. However, 78 (85.7%) of the
isolates were resistant to clindamycin and 61 (67.0%) had
a clindamycin MIC of greater than 256 µg/mL. Eighty-six
(94.5%) also displayed resistance to levofloxacin; 84
(92.3%) of 91 had a MIC greater than 32 µg/mL. A subset
of 10 isolates was similarly tested for susceptibility to
other quinolone antibiotics. All were resistant to ofloxacin
and ciprofloxacin and 70% were resistant to moxifloxacin
and gatifloxacin. Of the 45 isolates acquired elsewhere, 38
(84.4%) were resistant to clindamycin and 26 (57.8%) had
a clindamycin MIC of greater than 256 µg/mL. For the 46
nosocomial isolates, 40 (87.0%) were resistant to clin-
damycin and 35 (76.1%) had a clindamycin MIC of greater
than 256 µg/mL. There was no significant difference in
antimicrobial susceptibility between the nosocomial iso-
lates and those acquired elsewhere.
Of the 91 isolates available for antimicrobial sus-
ceptibility testing, 11 were type 2 and 14 were type 4. All
11 type 2 isolates were resistant to both levofloxacin (MIC
> 32 µg/mL) and clindamycin (MIC > 256 µg/mL). Of the
14 type 4 isolates, all were resistant to levofloxacin (MIC
> 32 µg/mL), and 13 (93%) were resistant to clindamycin
(MIC > 256 µg/mL). The remaining isolate had a MIC of
6 µg/mL for clindamycin, indicating intermediate resis-
tance. 
REA Type
REA was performed on 135 C. dif ficile isolates: 92
from patients with nosocomial infection and 43 from
patients who acquired their C. dif ficile infection else-
where. Among the nosocomial isolates, there were 36 dis-
tinct REA patterns. REA types 2 and 4, which differed
from each other by a single band, were the most frequent,
TABLE 1
MATCHED UNIVARIATE ANALYSIS OF SELECTED DEMOGRAPHICS AND CLINICAL CHARACTERISTICS OF CASE-PATIENTS AND CONTROL-
PATIENTS
Case-Patients Control-Patients Matched
Characteristic (n = 203) (n = 203) OR CI95 P
Male 104 (51.2%) 106 (52.2%) 0.96 0.6–1.5 .75
White 166 (82.2%) 164 (81.2%) 1.1 0.6–1.8 .80
Surgery service 122 (60.1%) 122 (60.1%) Matching 
criterion
Chronic medical condition
Organ transplantation 44 (21.7%) 18 (8.9%) 4.3 2.0–9.2 .0002
Diabetes 83 (40.9%) 59 (29.1%) 1.7 1.1–2.7 .01
Malignancy 54 (26.6%) 47 (23.2%) 1.2 0.8–1.9 .42
Chronic lung disease 68 (33.5%) 47 (23.2%) 1.6 1.1–2.5 .03
HIV infection 3 (1.5%) 4 (2.0%) 0.8 0.2–3.4 .71
Inflammatory bowel disease 4 (2.0%) 12 (5.9%) 0.3 0.1–1.03 .06
Diverticulosis 18 (8.9%) 6 (3.0%) 3.0 1.2–7.6 .02
Colostomy 3 (1.5%) 11 (5.4%) 0.2 0.04–0.9 .04
Short gut syndrome 1 (0.5%) 6 (3.0%) 0.2 0.02–1.4 .10
Chronic renal failure 37 (18.2%) 42 (20.7%) 0.8 0.5–1.4 .52
Immunosuppressed 70 (34.5%) 48 (23.6%) 1.9 1.2–3.1 .01
Previous history of Clostridium difficile infection 3 (1.5%) 2 (1.0%) 1.5 0.3–9.0 .66
Median LOS before case infection, d (range) 14 (3–100) 14 (1–102) Matching 
criterion
Median total LOS, d (range) 28 (5–234) 25 (3–174) .53
Median age, y (range) 64 (17–95) 59 (16–93) .10
OR = odds ratio; CI95 = 95% confidence interval; HIV = human immunodeficiency virus; LOS = length of stay.
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accounting for 18 (19.5%) and 29 (31.5%) of the isolates,
respectively. The other 34 REA types among the remain-
ing 45 isolates occurred at frequencies ranging from 1
(1.1%) to 5 (5.4%) of the isolates and only 5 (5.4%) of our
isolates were REA type J9. In a comparison of nosocomial
isolates and isolates acquired elsewhere, 47 (51.2%) ver-
sus 12 (27.9%), respectively, were REA types 2 or 4 (P =
.01). 
Among the 92 nosocomial isolates for which REA
data were available, hospital location data were available
for 87. REA type 2 was associated with case-patients
housed on the tenth floor of hospital A (P = .01), as well as
hospital A in general (P = .01). Of the 17 REA type 2 iso-
lates, 13 (76.5%) of the patients had been admitted to hos-
pital A, with 7 on the tenth floor, 3 on the ninth floor, and
an additional 2 patients spending time on both the ninth
and tenth floors. Type 4 was associated with hospital B: 21
(80.8%) of 26 patients with REA type 4 spent time in hos-
TABLE 2
MATCHED UNIVARIATE ANALYSIS OF SELECTED DRUGS ADMINISTERED TO CASE-PATIENTS AND CONTROL-PATIENTS DURING THE 4 WEEKS
BEFORE THE DETECTION OF CLOSTRIDIUM DIFFICILE TOXIN IN THE STOOL OF THE CASE-PATIENT
Case-Patients Control-Patients
Drug (n = 203) (n = 203) OR CI95 P
Antimicrobial agent
Ceftriaxone 21 (10.3%) 8 (3.9%) 3.2 1.3–7.9 .014
Clindamycin 32 (15.8%) 13 (6.4%) 2.7 1.4–5.4 .004
Cefuroxime 5 (2.5%) 2 (1.0%) 2.5 0.5–12.9 .27
Amoxicillin–clavulanate 5 (2.5%) 2 (1.0%) 2.5 0.5–12.9 .27
Antiviral class 43 (21.2%) 24 (11.8%) 2.5 1.3–4.7 .006
Levofloxacin 120 (59.1%) 83 (40.9%) 2.2 1.4–3.4 .0003
Sulfa class 33 (16.3%) 18 (8.9%) 2.2 1.1–4.2 .02
Antifungal class 71 (35.0%) 50 (24.6%) 2.1 1.2–3.6 .008
Cefepime 49 (24.1%) 28 (13.8%) 2.1 1.2–3.6 .008
Macrolide class 30 (14.8%) 16 (7.9%) 2.0 1.1–3.8 .03
Metronidazole 52 (25.6%) 39 (19.2%) 1.5 0.9–2.5 .10
Cephalosporin class 124 (61.1%) 109 (53.7%) 1.4 0.9–2.1 .11
Ampicillin 9 (4.4%) 7 (3.4%) 1.3 0.5–3.5 .62
Vancomycin (intravenous) 92 (45.3%) 81 (39.9%) 1.3 0.8–1.9 .27
Imipenem 8 (3.9%) 7 (3.4%) 1.1 0.4–3.2 .80
Ceftazidime 2 (1.0%) 2 (1.0%) 1.0 0.1–16.0 1.00
Ciprofloxacin 15 (7.4%) 15 (7.4%) 1.0 0.5–2.2 1.00
Tetracycline class 2 (1.0%) 2 (1.0%) 1.0 0.1–7.1 1.00
Piperacillin–tazobactam 62 (30.5%) 64 (31.5%) 0.95 0.6–1.5 .82
Cefazolin 81 (39.9%) 87 (42.9%) 0.9 0.6–1.3 .50
Ampicillin–sulbactam 15 (7.4%) 17 (8.4%) 0.9 0.4–1.8 .71
Cefotetan 13 (6.4%) 14 (6.9%) 0.9 0.4–2.0 .84
Aztreonam 8 (3.9%) 10 (4.9%) 0.8 0.3–2.0 .64
Rifampin 4 (2.0%) 5 (2.5%) 0.8 0.2–3.0 .74
Aminoglycoside class 33 (16.3%) 42 (20.7%) 0.7 0.4–1.2 .25
Cefotaxime 2 (1.0%) 3 (1.5%) 0.7 0.1–4.0 .66
Vancomycin (oral) 1 (0.5%) 2 (1.0%) 0.5 0.05–5.5 .57
Quinupristin–dalfopristin, linezolid, or both 1 (0.5%) 3 (1.5%) 0.3 0.04–3.2 .34
Other medications
Immunosuppressive drugs 52 (25.6%) 26 (12.8%) 3.2 1.7–6.1 .0005
Proton pump inhibitor 78 (38.4%) 54 (26.6%) 1.8 1.2–2.9 .009
H2 blocker 159 (78.3%) 141 (69.5%) 1.6 1.0–2.5 .04
Corticosteroids 92 (45.3%) 79 (38.9%) 1.4 0.9–2.1 .17
Anti-diarrheal medication 18 (8.9%) 12 (5.9%) 1.5 0.7–3.3 .26
Antacids 31 (15.3%) 36 (17.7%) 0.8 0.5–1.4 .49
Sucralfate 14 (6.9%) 11 (5.4%) 1.3 0.6–3.0 .53
Narcotic 182 (89.7%) 178 (87.7%) 1.2 0.7–2.3 .53
OR = odds ratio; CI95 = 95% confidence interval.
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pital B versus 29 (47.5%) of 61 patients with other REA
types (P = .01). 
Outbreak-Associated Costs
In 1999, prior to the onset of the outbreak, 72 C. dif-
ficile infections occurred at our institution. In 2000 and
2001, the average annual incidence of C. dif ficile disease
increased 2.5-fold in our institution from 2.7 cases per
1,000 discharges in 1999 to 6.8 cases per 1,000 dis-
charges, resulting in a total excess of 253 infections or an
average of 127 infections annually. The estimated attrib-
utable healthcare cost of these additional C. dif ficile
infections during 2000–2001 was $928,257. Additional
costs were likely to have been incurred as the proportion
of severe cases also increased significantly from 4 (5.6%)
of 72 in 1999 to 18 (8.4%) of 214 and 19 (9.3%) of 205 
in 2000 and 2001, respectively, with 26 C. dif ficile–associ-
ated colectomies and 18 C. dif ficile–associated deaths
noted.
DISCUSSION
The epidemiology of C. dif ficile at our institution
has changed. Although several recent case reports24-30
and a few case–control studies7,20,31,32 proposed an associ-
ation between quinolone use and C. dif ficile–associated
disease, no single large study has identified increased
quinolone use as a primary precipitory agent of an ongo-
ing C. dif ficile outbreak. The major finding of our investi-
gation was an independent association between C. dif fi-
cile–associated disease and exposure to levofloxacin. 
Although causation is difficult to infer from observa-
tional studies, we believe that the relationship between C.
difficile and levofloxacin was causal for several reasons.
First, fluoroquinolones, like most other antibiotics, have
recently been found to be associated with C. difficile infec-
tion at various institutions; suggesting that quinolone expo-
sure may be a promoter of this illness is biologically plau-
sible. Second, our particular outbreak was preceded by the
introduction of levofloxacin to our formulary and a large
increase in quinolone use; temporality is perhaps the most
fundamental criterion for inferring a causal relationship
from observational data. The reason for the occurrence of
a lag of approximately 9 months between the increase and
the onset of the outbreak is not clear. 
Ceftriaxone and clindamycin were also identified as
risk factors for disease in our study. Although exposure to
third-generation cephalosporins,16-20 specifically ceftriax-
one,17 and clindamycin is regarded as a well-established
risk factor for C. dif ficile infection,1,6,8,12-15,43 the magnitude
of the increased use of these antibiotics was small and the
proportion of cases that received these antibiotics was
less than 11% and 16%, respectively. The OR for the asso-
ciation between levofloxacin and C. dif ficile–associated
diarrhea was relatively modest (2.0) and lower than those
for clindamycin and ceftriaxone (4.8 and 5.4, respective-
ly). However, the etiologic fraction estimates clearly sug-
gested that levofloxacin was responsible for a greater pro-
portion of cases than were the other two agents. The large
number of patients included in the case–control study was
a major strength of this outbreak investigation and may
have permitted us to detect an association between lev-
ofloxacin and C. dif ficile–associated diarrhea that might
otherwise have gone unnoticed in a smaller study. 
A recent small study by Gaynes et al.31 also found an
association between fluoroquinolones and C. difficile dis-
ease. Their findings differed substantially from ours. They
demonstrated a difference in C. difficile colitis risk during
periods when two different fluoroquinolones (levofloxacin
and gatifloxacin) were used. Of note, the C. difficile disease
attack rate associated with each fluoroquinolone was high.
The authors speculated that the enhanced anaerobic spec-
trum of gatifloxacin may have had a more disruptive effect
on fecal flora and accounted for their increased rate.
Historically, the newer fluoroquinolone agents were found
to be more active against C. difficile than were the older flu-
oroquinolones.44 However, this study, like ours, found most
isolates to be resistant to all quinolones tested. As lev-
ofloxacin does not have the enhanced anaerobic spectrum
of gatifloxacin, we believe that perhaps the inability of lev-
ofloxacin to exhibit an inhibitory effect on C. difficile iso-
lates coupled with its increased use, along with concomi-
tant use of other antimicrobials, accounted for our
increased C. difficile rate. One additional case–control
study of C. difficile–associated disease done in 200132 also
found fluoroquinolone use (OR, 12.7; CI95, 2.6 to 61.6) to be
the only significant risk factor for C. difficile–associated dis-
ease. The primary fluoroquinolone used was levofloxacin
(60% of subjects), and only 15% of subjects were exposed to
gatifloxacin. Gaynes et al. did not report quinolone use dur-
ing their study. Perhaps their changing rates were associ-
ated with changing fluoroquinolone use and were less spe-
cific to which quinolone was used.
In an editorial accompanying the study by Gaynes
et al.,45 Gerding concurred that the anaerobic activity of
newer fluoroquinolones is likely to be more disruptive of
gut flora, but also believed that the additional factors of
acquired fluoroquinolone resistance in C. dif ficile and
proliferation of these resistant clones are the critical
events leading to hospital outbreaks. In addition, he sug-
gested that with this selected resistance and continued
exposure to any fluoroquinolone, infection rates may not
decrease. 
Several studies have documented clonal spread of
C. dif ficile in healthcare settings.8,46-49 REA type J9 is
often found as the predominant subtype in these out-
breaks.46 Unlike other facilities, our most prevalent REA
types (2 and 4) had not been previously described, and
REA type J9 was infrequently isolated during our out-
break. Although 28 distinct nosocomial REA types were
identified, more than half of the isolates belonged to 2
REA types that differed from each other by only 1 band;
preliminary plasmid analysis did not suggest that this 
difference was due to the presence of a plasmid (data not
shown). The analysis of these REA types by geographic
location indicates that these two strains behaved differ-
ently epidemiologically despite being highly related
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genetically. Taken together, the molecular and case–con-
trol study data suggest that both nosocomial transmis-
sion and antibiotic use contributed to this outbreak.
There are several limitations of this study. The
large number of variables we analyzed increased the like-
lihood that some of the associations we observed were
due to chance. However, the temporal relationship
between levofloxacin use and the onset of the outbreak,
as well as the well-established relationship between clin-
damycin and the third-generation cephalosporins and C.
dif ficile–associated disease, suggests that our main find-
ings were not spurious. The case–control study and mol-
ecular epidemiologic analysis were from essentially two
different, albeit contiguous, time periods. However, we
doubt that our findings would have differed substantially
if both study components had been from overlapping
periods. Finally, as most of our patients who received lev-
ofloxacin also received other antibiotics, we were not
able to examine the risk of levofloxacin monotherapy in
this study.23
Data from other settings suggest that aggressive
antibiotic restriction may be required to stem an out-
break.6,8 Many other hospitals are now reporting epidem-
ic rates of C. dif ficile–associated colitis. Conceivably, the
answer may not relate to changing from one quinolone to
another. Rate reduction might be accomplished only when
the use of fluoroquinolones, in general, is significantly
reduced.45 We have recently established an antibiotic
management program that will focus on promoting the
judicious use of antibiotics, as well as restricting the spe-
cific antibiotics implicated in this investigation and other
broad-spectrum antibiotics. Ongoing surveillance of C.
dif ficile disease will continue to assess whether this inter-
vention will control the outbreak.
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